STOCK TITAN

Vistagen (NASDAQ: VTGN) holder reports 4.71% passive stake

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Vistagen Therapeutics, Inc. received an updated ownership report from Nantahala Capital Management, LLC and its managing members Wilmot B. Harkey and Daniel Mack. As of December 31, 2025, they may be deemed to beneficially own 1,953,045 shares of common stock, representing 4.71% of the class.

All 1,953,045 shares are reported with shared voting and shared dispositive power, and no sole voting or dispositive power. The reporting group states the shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Vistagen.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:02/13/2026
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:02/13/2026
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:02/13/2026

FAQ

What ownership stake in Vistagen (VTGN) is reported in this Schedule 13G/A?

The filing reports beneficial ownership of 1,953,045 shares of Vistagen common stock, equal to 4.71% of the outstanding class as of December 31, 2025. This stake is disclosed as held on a shared voting and shared dispositive basis.

Who are the reporting persons in the Vistagen (VTGN) Schedule 13G/A?

The reporting persons are Nantahala Capital Management, LLC and its managing members Wilmot B. Harkey and Daniel Mack. Nantahala is a Massachusetts limited liability company; Harkey and Mack are U.S. citizens tied to the same 1,953,045 Vistagen shares.

How much voting and dispositive power do the Vistagen (VTGN) reporting persons have?

Each reporting person lists 0 shares with sole voting and sole dispositive power, and 1,953,045 shares with shared voting and shared dispositive power. This structure indicates decisions over the stake are made jointly rather than individually.

Is Nantahala’s Vistagen (VTGN) stake reported as a passive investment?

Yes. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control of Vistagen, other than activities tied to a nomination under Rule 240.14a-11.

Why does the Vistagen (VTGN) filing mention ownership of 5 percent or less?

Item 5 notes ownership of 5 percent or less of the class. With the reported 4.71% stake, the holders remain below the 5% threshold that often signals a larger, potentially more influential position in a public company’s equity.

What entity actually holds the Vistagen (VTGN) shares reported by Nantahala?

The 1,953,045 shares are held by funds and separately managed accounts under Nantahala’s control. Harkey and Mack, as managing members of Nantahala, may be deemed beneficial owners of the same shares through their roles at the investment adviser.
Vistagen Therapeutics Inc

NASDAQ:VTGN

VTGN Rankings

VTGN Latest News

VTGN Latest SEC Filings

VTGN Stock Data

21.53M
36.33M
0.34%
64.1%
3.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO